Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) & Geography
The global biosimulation market is projected to grow at a CAGR of 15.9% during the forecast period. Factors such as increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the market.
By product & service, the biosimulation software segment is expected to grow at the highest growth rate during the forecast period
Based on product & service, the biosimulation market is segmented into software and services. The biosimulation software segment is expected to account for the largest market share in 2017. The high growth in this segment is attributed to the growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
By end user, the pharmaceutical and biotechnology companies segment to record the highest CAGR during the forecast period
Based on end user, the biosimulation market is segmented into research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (consulting firms, defense research and development organizations, nutraceutical companies, and food and agricultural companies). In 2017, pharmaceutical and biotechnology companies are expected to form the largest share in 2017, and is projected to register the highest CAGR during the forecast period. Increased R&D budgets of pharmaceutical and biotechnology companies and increasing adoption of inorganic growth strategies by different biosimulation service providers are likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology industry.
North America to account for the largest market size during the forecast period.
The biosimulation market is segmented into four major regions, namely, North America, Europe, Asia, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes, increased use of personalized medicine, and increasing R&D expenditure by pharmaceutical and biotechnology companies.
Biosimulation Market Dynamics
Drivers: Growth in the biologics and biosimilar market
Growth in the global biosimilars market is mainly driven by factors such as the growing pressure to curtail healthcare expenditures, growing demand for biosimilars due to their cost-effectiveness, rising incidence of various diseases, increasing number of off-patented drugs, positive outcomes in ongoing clinical trials, and rising demand for biosimilars in different therapeutic applications such as rheumatoid arthritis and blood disorders. As there is very little success in the R&D of new chemical entities, pharmaceutical companies are trying to find new applications for their existing drugs. As toxicity and other vital parameters of drug safety are already tested, biosimulation technologies are used to confirm the hypothesis of using the drugs for a new indication or disease.
Restraints: Lack of standardization
Biosimulation uses a variety of models, tools, and languages for capturing and processing different aspects of biological processes. The current modeling methods do not capture the underlying semantics of biosimulation models to support building, reusing, composing, and merging of varied, complex biosimulation models. The governing bodies are yet to standardize the use of in silico or biosimulation technologies in the drug discovery or development process. Recent technological advancements have increased the computational power of biomedical researchers for building and managing complex biosimulation systems. However, as their models and simulations grow in complexity, researchers find it more difficult to share, manage, and edit their models. The problem of sharing complex biomedical models becomes severe with the lack of scalable standards for model representation and reuse. As a consequence, many model developers are unable to share and build new models upon previously coded models. This shortcoming of biosimulation can only be solved by the provision of a principled, standards-based representation model, which is able to represent biosimulation data unambiguously in both a human and a machine-interpretable way. The biosimulation community, therefore, has a growing need for tools that will help them to efficiently build, manage, and reuse their models.
Opportunities: Emerging applications
The emerging applications of biosimulation in defense, industrial bioprocessing, nutraceuticals, and agri-food production present significant opportunities for the growth of the global biosimulation market. Various biosimulation companies are adopting inorganic and organic growth strategies to expand the applications of their biosimulation software and services. In May 2017, the Institute of Life Science at Swansea University delivered an in silico drug discovery software platform for the UK Ministry of Defense for the development of antimicrobials to meet the needs of defense and security in the country. Likewise, in April 2017, Certara formed a partnership with the Australian Department of Defense. Certara’s d3 medicine company was selected to conduct a national audit to check the research and development capabilities and capacity of Australia’s medical countermeasures (MCM) product.
Challenges: Shortage of biosimulation and modeling experts
Biosimulation uses mathematical equations to represent real-life processes that take place inside of the human body. Because it can replicate human biological elements and their relationships to drugs when they are introduced into the system, researchers are able to simulate a wide variety of scenarios and study the behavior of a human system in different situations.
However, skilled expertise is required for running, planning, and monitoring biosimulation software. In research laboratories and companies, there is a high demand for researchers well-versed in biosimulation methods, such as molecular modeling and simulation and PK/PD modeling and simulation. Furthermore, the applications of biosimulation for various drug discovery and development purposes require various modified forms of molecular modeling and simulation and PK/PD modeling and simulation. These processes are highly technical and involve the use of various complex laboratory documentation systems; this necessitates training for the personnel carrying out biosimulation. It is important to provide adequate training and support to researchers in order to overcome this challenge. All these factors make biosimulation development a tedious process and thus limit its uptake among researchers.
Biosimulation Market Scope
Report Metric |
Details |
Market size available for years |
2015–2022 |
Base year considered |
2016 |
Forecast period |
2017–2022 |
Forecast units |
Million (USD) |
Segments covered |
Product & service, application, delivery model, end user, and region. |
Geographies covered |
North America, Europe, Asia, and Rest of the World |
Companies covered |
Certara (US), Simulations Plus (US), Dassault Systèmes (France), Schrödinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland) |
The research report categorizes the biosimulation to forecast the revenues and analyze the trends in each of the following sub-segments:
By Product & Service
-
Software
- Molecular Modeling and Simulation Software
- PBPK Modeling and Simulation Software
- PK/PD Modeling and Simulation Software
- Trial Design Software
- Toxicity Prediction Software
- Other Biosimulation Software
-
Services
- In-house Services
- Contract Services
By Application
-
Drug Development
-
Preclinical Testing
- PK/PD
- ADME/TOX
- Clinical Trials
-
Preclinical Testing
-
Drug Discovery
- Target Identification and Validation
- Lead Identification and Optimization
- Other Applications
By Delivery Model
- Subscription Models
- Ownership Models
By End User
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Contract Research Organizations
- Regulatory Authorities
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- RoE
- Asia
- Rest of the World (RoW)
Biosimulation Market Key Players
Certara (US), Simulations Plus (US), Dassault Systèmes (France), Schrödinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).
Recent Developments:
- In April 2017, Simulations Plus signed Distributor Agreement with Quantum Bio Solutions (Q-Bio) (South Korea) To strengthen its relationships with South Korean companies and universities
- In June 2017, Simulations Plus acquired DILIsym Services, Inc. (“DILIsym”) (US). This enabled the company to expand its product portfolio in simulation software and consulting services of drug-induced liver injury.
- In December 2015, Certara acquired XenologiQ (UK) To strengthen its product portfolio in mechanistic pharmacology and modeling and simulation
Critical questions the report answers:
- Where will all these developments take the industry in the long term?
- What are the upcoming trends for the biosimulation market?
- Which segment provides the most opportunity for growth?
- Who are the leading vendors operating in this market?
- What are the opportunities for new market entrants?
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Asia biosimulation market into India, China, and Japan.
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Frequently Asked Questions (FAQ):
How big is the Biosimulation Market?
Biosimulation Market worth $2,881 billion by 2022.
What is the growth rate of Biosimulation Market?
Biosimulation Market grows at a CAGR of 15.9% during the forecast period.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Table of Contents
1 Introduction (Page No. - 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders
2 Research Methodology (Page No. - 20)
2.1 Research Data
2.2 Secondary Data
2.2.1 Secondary Source
2.3 Primary Data
2.3.1 Primary Sources
2.3.2 Key Industry Insights
2.4 Market Size Estimation
2.5 Market Breakdown and Data Triangulation
2.6 Assumptions for the Study
3 Executive Summary (Page No. - 28)
4 Premium Insights (Page No. - 32)
4.1 Biosimulation Market Overview
4.2 Biosimulation Software Market, By Type
4.3 Geographic Analysis: Biosimulation Market in Europe, By End User and Country
4.4 Biosimulation Drug Developement Market, By Type
5 Market Overview (Page No. - 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries
5.2.1.2 Growing Adoption of Biosimulation Software By Regulatory Bodies
5.2.1.3 Technologically Advanced Qsp Systems
5.2.1.4 Need to Curtail Drug Discovery and Development Costs
5.2.1.5 Growth in the Biologics and Biosimilars Markets
5.2.2 Restraint
5.2.2.1 Lack of Standardization
5.2.3 Opportunities
5.2.3.1 Emerging Applications
5.2.3.2 Increased Use of Personalized Medicine
5.2.3.3 Use of Biosimulation Solution for Pediatric Drug Development
5.2.4 Challenges
5.2.4.1 Difficulty in Matching the Complexity of Biological Systems and Processes
5.2.4.2 Shortage of Biosimulation and Modeling Experts
6 Biosimulation Market, By Product & Service (Page No. - 40)
6.1 Introduction
6.2 Software
6.2.1 PK/PD Modeling and Simulation Software
6.2.2 Molecular Modeling and Simulation Software
6.2.3 Pbpk Modeling and Simulation Software
6.2.4 Toxicity Prediction Software
6.2.5 Trial Design Software
6.2.6 Other Biosimulation Software
6.3 Services
6.3.1 In-House Services
6.3.2 Contract Services
7 Biosimulation Market, By Application (Page No. - 58)
7.1 Introduction
7.2 Drug Development
7.2.1 Preclinical Testing
7.2.1.1 PK/PD
7.2.1.2 ADME/TOX
7.2.2 Clinical Trials
7.3 Drug Discovery
7.3.1 Target Identification and Validation
7.3.2 Lead Identification and Optimization
7.4 Other Applications
8 Biosimulation Market, By Delivery Model (Page No. - 76)
8.1 Introduction
8.2 Subscription Models
8.3 Ownership Models
9 Biosimulation Market, By End User (Page No. - 82)
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Research Institutes
9.4 Contract Research Organizations
9.5 Regulatory Authorities
9.6 Other End Users
10 Biosimulation Market, By Region (Page No. - 94)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Rest of Europe (RoE)
10.4 Asia
10.5 Rest of the World (RoW)
11 Competitive Landscape (Page No. - 140)
11.1 Overview
11.2 Market Ranking Analysis, 2016
11.3 Competitive Scenario
11.3.1 Product Launches and Approvals
11.3.2 Agreements, Partnerships, and Collaborations
11.3.3 Acquisitions
11.3.4 Expansions
12 Company Profiles (Page No. - 144)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
12.1 Certara
12.2 Simulation Plus
12.3 Dassault Systèmes
12.4 Schrödinger
12.5 Advanced Chemistry Development
12.6 Chemical Computing Group
12.7 Rosa
12.8 Genedata
12.9 Physiomics
12.10 Evidera
12.11 In Silico Biosciences
12.12 Leadinvent Technologies
12.13 Inosim Software
12.14 Nuventra Pharma
12.15 Insilico Biotechnology
*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 171)
13.1 Insights Form Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (187 Tables)
Table 1 Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 2 Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 3 Biosimulation Software Market, By Region, 2015–2022 (USD Million)
Table 4 North America: Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 5 Europe: Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 6 PK/PD Modeling and Simulation Software Market, By Region, 2015–2022 (USD Million)
Table 7 North America: PK/PD Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 8 Europe: PK/PD Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 9 Molecular Modeling and Simulation Software Market, By Region, 2015–2022 (USD Million
Table 10 North America: Molecular Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 11 Europe: Molecular Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 12 Pbpk Modeling and Simulation Software Market, By Region, 2015–2022 (USD Million)
Table 13 North America: Pbpk Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 14 Europe: Pbpk Modeling and Simulation Software Market, By Country, 2015–2022 (USD Million)
Table 15 Toxicity Prediction Software Market, By Region, 2015–2022 (USD Million)
Table 16 North America: Toxicity Prediction Software Market, By Country, 2015–2022 (USD Million)
Table 17 Europe: Toxicity Prediction Software Market, By Country, 2015–2022 (USD Million)
Table 18 Trial Design Software Market, By Region, 2015–2022 (USD Million)
Table 19 North America: Trial Design Software Market, By Country, 2015–2022 (USD Million)
Table 20 Europe: Trial Design Software Market, By Country, 2015–2022 (USD Million)
Table 21 Other Biosimulation Software Market, By Region, 2015–2022 (USD Million)
Table 22 North America: Other Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 23 Europe: Other Biosimulation Software Market, By Country, 2015–2022 (USD Million)
Table 24 Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 25 Biosimulation Services Market, By Region, 2015–2022 (USD Million)
Table 26 North America: Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 27 Europe: Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 28 In-House Biosimulation Services Market, By Region, 2015–2022 (USD Million)
Table 29 North America: In-House Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 30 Europe: In-House Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 31 Contract Biosimulation Services Market, By Region, 2015–2022 (USD Million)
Table 32 North America: Contract Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 33 Europe: Contract Biosimulation Services Market, By Country, 2015–2022 (USD Million)
Table 34 Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 35 Market for Drug Development, By Type, 2015–2022 (USD Million)
Table 36 Market for Drug Development, By Region, 2015–2022 (USD Million)
Table 37 North America: Biosimulation Market for Drug Development, By Country, 2015–2022 (USD Million)
Table 38 Europe: Market for Drug Development, By Country, 2015–2022 (USD Million)
Table 39 Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 40 Market for Preclinical Testing, By Region, 2015–2022 (USD Million )
Table 41 North America: Market for Preclinical Testing, By Country, 2015–2022 (USD Million)
Table 42 Europe: Market for Preclinical Testing, By Country, 2015–2022 (USD Million)
Table 43 Market for PK/PD, By Region, 2015–2022 (USD Million)
Table 44 North America: Market for PK/PD, By Country, 2015–2022 (USD Million)
Table 45 Europe: Market for PK/PD, By Country, 2015–2022 (USD Million)
Table 46 Market for ADME/TOX, By Region, 2015–2022 (USD Million)
Table 47 North America: Biosimulation Market for ADME/TOX, By Country, 2015–2022 (USD Million)
Table 48 Europe: Market for ADME/TOX, By Country, 2015–2022 (USD Million)
Table 49 Market for Clinical Trials, By Region, 2015–2022 (USD Million)
Table 50 North America: Biosimulation Market for Clinical Trials, By Country, 2015–2022 (USD Million)
Table 51 Europe: Market for Clinical Trials, By Country, 2015–2022 (USD Million)
Table 52 Market for Drug Discovery, By Type, 2015–2022 (USD Million )
Table 53 Market for Drug Discovery, By Region, 2015–2022 (USD Million)
Table 54 North America: Biosimulation Market for Drug Discovery, By Country, 2015–2022 (USD Million)
Table 55 Europe: Market for Drug Discovery, By Country, 2015–2022 (USD Million)
Table 56 Market for Target Identification and Optimization, By Region, 2015–2022 (USD Million)
Table 57 North America: Biosimulation Market for Target Identification and Validation, By Country, 2015–2022 (USD Million)
Table 58 Europe: Market for Target Identification and Validation, By Country, 2015–2022 (USD Million)
Table 59 Biosimulation Market for Lead Identification and Optimization, By Region, 2015–2022 (USD Million)
Table 60 North America: Market for Lead Identification and Optimization, By Country, 2015–2022 (USD Million)
Table 61 Europe: Market for Lead Identification and Optimization, By Country, 2015–2022 (USD Million)
Table 62 Biosimulation Market for Other Applications, By Region, 2015–2022 (USD Million )
Table 63 North America: Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 64 Europe: Biosimulation Market for Other Applications, By Country, 2015–2022 (USD Million)
Table 65 Global Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 66 Global Biosimulation Market for Subscription Models, By Region, 2015–2022 (USD Million)
Table 67 North America: Biosimulation Market for Subscription Models, By Country, 2015–2022 (USD Million)
Table 68 Europe: Biosimulation Market for Subscription Models, By Country, 2015–2022 (USD Million)
Table 69 Global Biosimulation Market for Ownership Models, By Region, 2015–2022 (USD Million)
Table 70 North America: Biosimulation Market for Ownership Models, By Country, 2015–2022 (USD Million)
Table 71 Europe: Biosimulation Market for Ownership Models, By Country, 2015–2022 (USD Million)
Table 72 Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 73 Biosimulation Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 74 North America: Biosimulation Market for Pharmaceutical & Biotechnology Companies, By Country, 2015–2022 (USD Million)
Table 75 Europe: Biosimulation Market for Pharmaceutical & Biotechnology Companies, By Country, 2015–2022 (USD Million)
Table 76 Biosimulation Market for Research Institutes, By Region, 2015–2022 (USD Million)
Table 77 North America: Biosimulation Market for Research Institutes, By Country, 2015–2022 (USD Million)
Table 78 Europe: Biosimulation Market for Research Institutes, By Country, 2015–2022 (USD Million)
Table 79 Biosimulation Market for Contract Research Organizations, By Region, 2015–2022 (USD Million)
Table 80 North America: Biosimulation Market for Contract Research Organizations, By Country, 2015–2022 (USD Million)
Table 81 Europe: Biosimulation Market for Contract Research Organizations, By Country, 2015–2022 (USD Million)
Table 82 Biosimulation Market for Regulatory Authorities, By Region, 2015–2022 (USD Million)
Table 83 North America: Biosimulation Market for Regulatory Authorities, By Country, 2015–2022 (USD Million)
Table 84 Europe: Biosimulation Market for Regulatory Authorities, By Country, 2015–2022 (USD Million)
Table 85 Biosimulation Market for Other End Users, By Region, 2015–2022 (USD Million)
Table 86 North America: Biosimulation Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 87 Europe: Biosimulation Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 88 Biosimulation Market, By Region, 2015–2022 (USD Million)
Table 89 North America Biosimulation Market, By Country, 2015–2022 (USD Million)
Table 90 North America: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 91 North America: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 92 North America: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 93 North America: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 94 North America: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 95 North America: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 96 North America: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 97 North America: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 98 North America: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 99 US: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 100 US: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 101 US: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 102 US: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 103 US: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 104 US: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 105 US: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 106 US: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 107 US: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 108 Canada: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 109 Canada: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 110 Canada: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 111 Canada: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 112 Canada: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 113 Canada: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 114 Canada: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 115 Canada: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 116 Canada: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 117 Europe: Pharmaceutical R&D Expenditure, By Country, 2015
Table 118 Europe: Biosimulation Market, By Country, 2015–2022 (USD Million)
Table 119 Europe: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 120 Europe: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 121 Europe: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 122 Europe: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 123 Europe: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 124 Europe: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 125 Europe: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 126 Europe: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 127 Europe: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 128 Biotechnology Industry in Germany (2009 vs 2016)
Table 129 Germany: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 130 Germany: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 131 Germany: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 132 Germany: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 133 Germany: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 134 Germany: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 135 Germany: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 136 Germany: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 137 Germany: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 138 UK: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 139 UK: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 140 UK: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 141 UK: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 142 UK: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 143 UK: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 144 UK: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 145 UK: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 146 UK: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 147 France: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 148 France: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 149 France: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 150 France: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 151 France: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 152 France: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 153 France: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 154 France: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 155 France: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 156 RoE: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 157 RoE: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 158 RoE: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 159 RoE: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 160 RoE: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 161 RoE: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 162 RoE: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 163 RoE: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 164 RoE: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 165 Asia: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 166 Asia: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 167 Asia: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 168 Asia: Market, By Application, 2015–2022 (USD Million)
Table 169 Asia: Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 170 Asia: Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 171 Asia: Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 172 Asia: Market, By Delivery Model, 2015–2022 (USD Million)
Table 173 Asia: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 174 RoW: Biosimulation Market, By Product & Service, 2015–2022 (USD Million)
Table 175 RoW: Biosimulation Software Market, By Type, 2015–2022 (USD Million)
Table 176 RoW: Biosimulation Services Market, By Type, 2015–2022 (USD Million)
Table 177 RoW: Biosimulation Market, By Application, 2015–2022 (USD Million)
Table 178 RoW: Biosimulation Market for Drug Development Applications, By Type, 2015–2022 (USD Million)
Table 179 RoW: Biosimulation Market for Preclinical Testing, By Type, 2015–2022 (USD Million)
Table 180 RoW: Biosimulation Market for Drug Discovery Applications, By Type, 2015–2022 (USD Million)
Table 181 RoW: Biosimulation Market, By Delivery Model, 2015–2022 (USD Million)
Table 182 RoW: Biosimulation Market, By End User, 2015–2022 (USD Million)
Table 183 Rank of Companies in the Global Biosimulation Market, 2016
Table 184 Product Launches and Approvals
Table 185 Agreements, Partnerships, and Collaborations
Table 186 Acquisitions
Table 187 Expansions
List of Figures (28 Figures)
Figure 1 Research Design: Biosimulation Market
Figure 2 Break Down of Primary Interviews: By Company, Designation, and Region
Figure 3 Market Estimation: Bottom-Up Approach
Figure 4 Global Market Size of the Biosimulation Market: Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Biosimulation Software to Dominate the Biosimulation Market in 2017 and 2022
Figure 7 Drug Development Segment to Dominate the Biosimulation Applications Market in 2017 and 2022
Figure 8 Subscription Model Segment to Dominate the Delivery Model Segment of Biosimulation Market in 2017 and 2022
Figure 9 Pharmaceutical & Biotechnology Companies to Dominate the Biosimulation End-User Market
Figure 10 Europe to Witness High Growth During the Forecast Period (2017–2022)
Figure 11 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries to Drive the Growth of the Market
Figure 12 PK/PD Modeling and Simulation Software to Account for the Largest Market Size in 2017 and 2022
Figure 13 Pharmaceutical & Biotechnology Companies to Account for the Largest Share of the Biosimulation Market in Europe in 2017
Figure 14 Preclinical Testing to Witness High Growth From 2017 to 2022
Figure 15 Biosimulation Market: Drivers, Restraints, Opportunities, and Challenges
Figure 16 Software Segment to Dominate the Biosimulation Market in 2017
Figure 17 Drug Development Segment to Dominate the Biosimulation Market During the Forecast Period
Figure 18 Ownership Models Segment to Offer Significant Growth Opportunities During the Forecast Period
Figure 19 Biosimulation Market, By End User, 2017 vs 2022 (USD Million)
Figure 20 Biosimulation Market in Europe to Witness the Highest Growth Rate During the Forecast Period
Figure 21 North America: Biosimulation Market Snapshot
Figure 22 Europe: Biosimulation Market Snapshot
Figure 23 Asia: Biosimulation Market Snapshot
Figure 24 RoW: Biosimulation Market Snapshot
Figure 25 Market Evolution Framework
Figure 26 Simulation PlUS: Company Snapshot (2016)
Figure 27 Dassault Systèmes: Company Snapshot (2016)
Figure 28 Physiomics : Company Snapshot (2017)
Growth opportunities and latent adjacency in Biosimulation Market